In this issue, Güzel Özdemir and colleagues have shown that treatment of severe major depression can now be greatly improved by safe, simple, and readily-available bright light treatment. Patients may benefit within a week. Moreover, the benefit persisted throughout 8 weeks of observation even after the bright light treatment was discontinued.
What seemed unique in this new study is the focus on hospitalized patients with severe nonseasonal unipolar depression and the treatment combination of bright light with the SNRI venlafaxine, contrasted with venlafaxine alone. Also unusual is the well-constructed design with just one week of treatment followed by 7 more weeks of observed remission. When bright light was combined with venlafaxine, substantially faster amelioration of symptoms began in the first week, and the advantage of one week of bright light treatment persisted throughout 8 weeks. In the first week, the benefit of bright light added to venlafaxine was more than double the benefit of venlafaxine on the Beck and POMS depression ratings, and almost double for the Hamilton depression ratings. Hamilton Depression Ratings were reduced from 29.9 at baseline to 5.7 at 8 weeks in the combination group, a most excellent response. No substantial adverse effects were observed attributable to bright light.
The cost of inpatient bright light treatment is almost negligible, since light treatment devices may be reused many times, whereas the cost-saving of faster remissions could be considerable. It is estimated that world-wide, perhaps a million patients have tried bright light treatment (much of it unsupervised at home), so we have considerable experience with bright light's safety. Some investigators have argued that blue light (e.g., 450-500 nm) of lower perceived intensity would be less disturbing and as effective as bright white light. It is likely that the main therapeutic effects of bright light are mediated by intrinsically photosensitive retinal ganglion cells exciting the circadian clock in the suprachiasmatic nuclei. Since the main photopigment of these ganglion cells is melanopsin, a special photopigment most sensitive to blue 450-480 nm light, blue light was tested and found more efficient than white light in some circadian phaseshifting and melatonin suppression experiments. More recent data show that rods and retinal cones sensitive to other light wavelengths have some role. 5 Small controlled trials of blue LED light with winter depression patients have been promising, [6] [7] [8] and blue light may be subjectively less glaring than equipotent white light. Unfortunately, as we age, the ocular lens becomes yellow and masks an increasing portion of blue light, so that any advantages of blue light might diminish in middle age. Also, it is believed that bright blue light, even within safety guidelines, has far more potential for retinal damage than equivalent white light. Thomas Insel, Director of the U.S. National Institute of Health, has decried a lack of progress in identifying new treatments providing better control of mental illnesses, of which major depression causes the most world-wide disability. 11, 12 The bright light study in this issue exemplifies a breakthrough in treating major depression. As Dr. Insel has declared, future clinical trials should clarify the underlying neurobiology mediating the treatment response. Does bright light work through retinal melanopsin neurons that phase-shift or suppress melatonin? Is the effect mediated by the same neurotransmitters impacted by SNRI drugs, or is the bright light effect mediated through pars tuberalis synthesis of TSH causing increased T3 (triiodothyronine) in the hypothalamus, as suggested by contemporary research about photoperiodism? 13 These are some questions for a new mechanism-based series of clinical trials.
